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The objective of this study was to estimate the protective effect of Bacille Calmette-Gue´rin (BCG) vaccine against tuberculosis
among (predominantly immunodeficient) HIV-infected children in Angola. A hospital-based case-control study was conducted
with 230 cases, children coinfected with tuberculosis, and 672 controls, HIV-infected children from the same hospital, aged 18
months to 13 years. The presence of a vaccination scar was taken as a proxy marker for BCG vaccination. The crude effectiveness
was 8% (95% CI: −26 to 32) and the adjusted effectiveness was 30% (95% CI: −75 to 72). The present study suggests that BCG does
not have a protective effect against tuberculosis among immunodeficient HIV-infected children. Since BCG is no longer given to
HIV-infected children, the study may not be replicated. Accepting that these findings should be considered with caution, they are
nonetheless likely to be the last estimate of BCG efficacy in a sufficiently powered study.
1. Introduction
Tuberculosis (TB) remains a public health problem world-
wide. It is estimated that in 2012 there were 8.6 million
incident cases, 13% of which included people living with
HIV, with 1.3 million deaths (940,000 among HIV-negative
individuals and 320,000 among HIV-positive) [1]. In Angola,
the incidence of TB was 320 per 100000 inhabitants [2]; it was
estimated that among adults aged 15 to 49 the prevalence rate
of HIV was 2.4% [3].
The only licensed vaccine for the prevention of TB and
leprosy is Bacille Calmette-Guerin (BCG) [4]. However, there
has been much debate regarding the advantages and dis-
advantages of BCG since its use was first introduced. Key
elements of the debate surrounding the effectiveness of BCG
have included safety, loss of tuberculin sensitivity as a diag-
nostic tool, and, especially, the broad range of BCG effec-
tiveness against TB, in 17 trials and 10 case-control studies,
from no protection to 83% (95% CI: 58% to 93%) [5].
Available data have consistently suggested that BCG
protects against severe forms of TB. A meta-analysis on the
efficacy of BCG vaccination in newborns and infants in the
prevention of TB demonstrated that BCG vaccine provided
a protective effect of 71% against TB deaths and 64% against
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TB meningitis [5]. A further meta-analysis revealed a BCG
protective effect of 86% against miliary or meningeal TB in
randomized controlled trials and 75% in case-control studies
[6].Thequestion ofwhether BCG strains (which evolvedwith
different mutations along time) provide different degrees of
protection against TB has been raised [7–9], but the epidemi-
ological evidence is that strains variation does not explain
variation in protection [10].
The AIDS pandemic ravaging sub-Saharan Africa has
brought about increased challenges for the BCG vaccine,
particularly with regard to its safety [11–15] and effectiveness.
For countries with a high burden of TB, in 2004, World
HealthOrganization recommended a single dose of BCGvac-
cine after birth, unless the child presented with symptomatic
HIV infection [16]. When the study was being conducted,
vaccination of HIV-infected children was carried out accord-
ing to this recommendation. However, due to evidence that
HIV-infected children vaccinated with BCG at birth, who
later went on to develop AIDS, presented a higher risk of
disseminated BCG disease, WHO changed its recommenda-
tion and children who are known to be HIV-infected, even
asymptomatic, should no longer be immunizedwith the BCG
vaccine [17].
In Angola, BCG has been administered since the 1970s.
Vaccine is given at birth or on the first contact with
health institutions. The strain of BCG vaccine used is BCG-
Connaught (BCG vaccine, Sanofi-aventis, Quebec, Canada),
administered with the manufacturer’s recommended dose.
With the available studies, it is not possible to obtain
definitive conclusions regarding the effectiveness of BCG
in protecting against TB in HIV-infected, immunodeficient
children and adults [18, 19].
The present study was proposed to evaluate the effective-
ness of the BCG vaccine against TB in HIV-infected, pre-
dominantly immunodeficient children in a tertiary hospital
in sub-Saharan Africa.
2. Patients and Methods
2.1. Study Population. The study population consisted of
HIV-infected, predominantly immunodeficient children
aged 18 months to 13 years treated at Hospital Pedia´trico
David Bernardino (HPDB) in Angola from January 2005 to
December 2006.
2.2. Study Design and Definition of Cases and Controls. We
conducted a hospital-based case-control study. All HIV-
infected children, both in- and outpatients, were investigated.
Cases included HIV-infected children diagnosed with TB
according to WHO criteria for TB adapted for areas of high
HIVprevalence [21] and classified as confirmed andprobable.
Children were assigned for investigation of TB according
to at least one of the following criteria for suspicion of TB:
contact with confirmed or presumed TB cases; not regaining
normal health after measles or whooping cough; fever and/or
cough for more than 2 weeks after treatment (including
antibiotics for common pathogens); weight loss/failure to
gain weight/moderate to severe malnutrition; generalized
lymphadenopathy and/or regional lymphadenitis; meningeal
syndrome, thoracic spinal deformity; and changes on chest
X-ray, which did not improve after antibiotic treatment for
common agents.
(1) Confirmed Diagnosis (One of the Criteria Listed)
(a) Detection of the tuberculous bacilli in tissues or secre-
tions by microscopy or culture (requires two posi-
tive samples by microscopic examination if fluid or
pulmonary secretion).
(b) Identification of the bacillus TB as Mycobacterium
tuberculosis in culture.
(2) Probable Diagnosis (Probable Diagnosis, If at Least
Three Points Are Verified)
(a) History of contact with suspected or confirmed case
of TB.
(b) Tuberculin skin test ≥ 5mm.
(c) Chest X-ray findings suggestive of TB.
(d) Histological appearance suggestive of TB in biopsy
material.
(e) Cytochemical examination of body fluids (pleural
fluid, cerebrospinal fluid, and peritoneal fluid) com-
patible with TB.
(f) Favorable response to anti-TB treatment.
The selected cases represented all cases of tuberculosis in
HIV-infected children during the study period, and controls
were the consecutive HIV-positive children treated at and/or
admitted to the same hospital but with no clinical evidence of
TB at a ratio of 3 controls per case. Diagnosis ofHIV infection
was performed in accordance with the standards of the
AngolanMinistry ofHealth [22] (see SupplementaryMaterial
available online at http://dx.doi.org/10.1155/2015/275029 for
diagnostic criteria and exams).
2.3. Establishing Exposure and Procedures for Data Collection.
BCG vaccination was identified by the presence of scar
observed on the deltoid region of the left arm [22]. Results
were coded and kept secret until completion of the exams,
which would thus either allow inclusion as a case or control
or exclusion. Identification was undertaken by nursing staff
blinded to the outcome of the study. Interviews were per-
formed using a standardized questionnaire. The interviewer,
the personnel performing the diagnostic tests, and the three
physicians who collected the clinical history and conducted
the physical examinationswere unaware of themain exposure
and outcome.
Data were coded, checked, and double entered. At the end
of the investigation, the researcher, unaware of the children’s
vaccination status, gathered together all information regard-
ing the clinical history, physical examination, and comple-
mentary exams and allocated the children to the case group
(confirmed or probable) or the control group, according
to WHO criteria for TB (adapted for areas of high HIV
prevalence) [21].
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2.4. Sample Size. The estimated sample size was 225 cases
and 675 controls, based on a ratio of three controls per case,
assuming a protective effect of 36% [23], with an estimated
coverage of 62%, [20] a power of 80%, and an alpha level of
0.05.We used the Epi Infomodule 6.04d (2001, CDC,Atlanta,
GA).
2.5. Statistical Analysis. Analysis was performed using Epi
Info 6.04d and SPSS 11.0 for Windows (SPSS Inc, Chicago,
USA). Crude and adjusted odds ratios and their respective
95% confidence intervals were estimated. Vaccine effective-
ness was estimated as (1 − OR) × 100 [24].
A logistic regression model was used considering TB
(confirmed diagnosis, probable diagnosis, and overall assess-
ment) as the dependent variable and scar as the main
explanatory variable. The potentially confounding variables
were grouped into blocks of variables: biological (age in 3
groups, gender), family structure (orphaned, sibling died of
AIDS, and relationship to the head of the family), healthcare
(where treated: hospital or outpatient clinic, vaccines regis-
tered in accordance with the expanded program on immu-
nization (EPI), regularity of AIDS consultations, adherence
to antiretroviral medication, and distance to health center),
socioeconomic (head of family’s education, employment
status, family income, number of people living at household,
and housing conditions), and clinical condition (mode of
HIV transmission, history of TB and pneumonia, contact
with TB, nutritional status, clinical category of HIV infection,
and degree of immunodeficiency). Investigation of the con-
founding factors was conducted using the following steps:
(a) Confounding criteria: an OR ≥ 1.4 and/or 𝑝 ≤ 0.20,
in association with TB in the unvaccinated group
and/or in association with exposure (scar) in the
control group, in the univariate analysis; we adopted
the cut-off point of OR > 1.4 with 𝑝 ≤ 0.2 for we
assumed that a variable that would reach these values
in the association with exposure and disease would be
likely to distort the association between exposure and
disease.
(b) Adjustment of the variables within the same block.
Those with 𝑝 ≤ 0.10 were kept in the model.
(c) Adjustment of the OR of the association between
BCG vaccine and TB for the variables of each block.
The age variable remained in the model in all blocks
(Table 3).
The effectiveness of BCG was first adjusted for the vari-
ables that met the criteria for confounding within each block.
These variables were then included in the final regression
model, and those with 𝑝 ≤ 0.05 remained in the model
(Table 3).
The sensitivity and specificity of BCG scar reading com-
pared with the vaccination card, and information from par-
ents or guardians as gold standards, in the same group of chil-
dren, has been published elsewhere by the same authors [20].
Sensitivity ranged from 81.3% (95% CI: 78.0–84.2) to 91.6%
(95% CI: 88.4–94.0) when the gold standards were, respec-
tively, information from the adult responsible for the child
and the vaccination card. Specificity ranged from 90.5% (95%
CI: 81.6–95.5) to 94.1% (95% CI: 87.7–97.4) when the gold
standards were, respectively, the vaccination card and infor-
mation from the adult responsible for the child.
Crude and adjusted effectiveness of BCG vaccination was
calculated based on the presence of BCG scar and on the
vaccination card. To assess the validity of the BCG scar, only
those children who presented both information from parents
or guardians and vaccination cardswere considered (502 chil-
dren) [20]. However, in the present adjusted analysis of the
protective effect, we selected all children with a vaccination
card (541 children) without considering whether information
from parents or guardians was available (Table 3).
Effectiveness of BCG was evaluated in relation to the
pulmonary and extrapulmonary forms of TB (Table 5). We
did not estimate separate efficacy for immunocompetent and
immunodeficient children because of the small number of
immunocompetent children.
3. Results
3.1. Selection of the Study Population. A total of 231 cases were
recruited. Of these, one was excluded because staff respon-
sible for X-ray reading discovered the diagnostic hypothesis
before delivering the report, which could have led to misclas-
sification. A total of 230 cases and 672 controls were selected.
Exclusion criteria and number of patients excluded are pre-
sented in Figure 1.Of the 230 cases, 156 (67.8%)were recruited
from inpatients, while this percentage was 33% among the
controls.
Of the 230 cases, 200 (86.9%) presented with pulmonary
TB, of which 4 (2.0%) had severe pleural involvement. Extra-
pulmonary tuberculosis was identified in 30 cases, 13 of which
(43%) presentedwithmiliary TB; 5 (17%) presentedwith gan-
glionary TB; 5 presented with TB meningitis. Among cases,
15.2% were aged below 37 months, 41.3% were aged between
37 and 60 months, and 43.5% were aged 60 months and over;
52.6%weremales. Of the 672 controls, 36.9%were aged below
37 months, 40.4% were aged between 37 and 60 months, and
22.6% were aged 60 months and over; 52.5% of controls were
females.Themedian age of cases was 4.83 and 3.50 among the
controls.
Table 1 presents a comparison of the main characteristics
of cases and controls.
Table 2 presents the odds ratios and effectiveness of the
association between BCG vaccination and TB according to
different diagnostic categories. BCG scar was observed in
62.6% of the cases and in 64.4% of the controls. These results
are similar to those observed when considering the cate-
gories of probable and confirmed diagnoses independently
(Table 2).
In Table 3, we present the OR of the association between
TB and BCG adjusted for the variables that remained in
the multivariate model of each block of variables, where
age remained in all models. The OR values ranged from
0.79 (when adjusted for healthcare variables) to 1.14 (when
adjusted for clinical conditions variables). This association
was not statistically significant in any of the blocks. Addition-
ally, there was an overlap of the confidence intervals; hence
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Recruited population
231 cases; 680 controls
13 controls (primary
refusal)
231 cases; 677 controls
3 controls (doubtful
scar)
1 case (unblinde
230 cases; 677 controls
5 controls 
230 cases 672 controls 
Probable (n = 174) Confirmed (n = 56)
13 (culture) 43 (smear)
d∗)
Figure 1: Selection of the study population. ∗Staff responsible for the X-ray reading discovered the diagnostic hypothesis before delivering
the report.
there was no difference between them, and no wide confi-
dence intervals were observed.
The median age of the children was 3.66 for those with a
vaccination card and 3.91 for those with no vaccination card.
Crude and adjusted effectiveness of BCG vaccination
based on the presence of BCG scar and on the vaccination
card is demonstrated in Table 4.The crude and adjusted effec-
tiveness, based on BCG scar when all children were consid-
ered, was 8% (95%CI:−26 to 32) and 30% (95%CI:−75 to 72),
respectively. When only the subgroup of children with a vac-
cination cardwas estimated (𝑛 = 541), the crude effectiveness
was 29% (95% CI: −14 to 56) if based on the vaccination card
and 16% (95% CI: −32 to 47) if based on the scar (Table 4).
In an exploratory analysis, it was discovered that, among
childrenwith both the pulmonary and extrapulmonary forms
of TB, the percentage of those vaccinated was similar to that
observed amongst the controls.The effectiveness observed for
pulmonary forms was close to the crude effectiveness for all
children (Table 5).
The median ages of children with pulmonary and extra-
pulmonary forms were 4.83 and 4.96 years, respectively.
We compared probable and confirmed caseswith controls
in relation to clinical criteria (cough, sputum production,
breathlessness, and fever), TST, history of contact with some-
one with TB, and variables related to HIV/AIDS (previous
diagnosis of HIV, immunodeficiency, and clinical category of
HIV (CDC)).The results showed that the group of confirmed
and probable cases were very similar in relation tomost of the
above mentioned factors and that they differed from controls
(data not shown), suggesting that the degree of misclassifica-
tion in relation to the diagnostic (TB) was not large.
To evaluate the potential bias introduced by inclusion of
TST≥ 5mm in the definition of probable TBwe tested if there
was an association between the induration size and BCG
vaccination. In cases the frequency of TST ≥ 5mm was high
in vaccinated (96.53%) and in unvaccinated (91.86%) (𝑝 =
0.124), while in controls it was low in vaccinated (2.78%) and
in unvaccinated (6.00%) (𝑝 = 0.377).
4. Discussion
This is the first study carried out in Angola to assess the
protective effect of BCG in HIV-infected children. There has
only ever been one other very small study conducted in Zam-
bia, which estimated BCG efficacy in HIV-infected children
[25]. Our findings suggest that the first dose of BCG has
no protective effect against TB in these children.
Due to the lack of studies provided by the literature, the
protective effect of BCG in HIV-infected individuals is still
unclear. A case-control study was conducted with Colombian
adults but with a small sample size (88 cases and 88 controls)
[26], and although the protective effect against all forms of TB
BioMed Research International 5
Table 1: Comparison of the main characteristics of cases (TB/HIV-infected children) and controls (HIV-infected children). Hospital
Pedia´trico David Bernardino (HPDB, Angola): January 2005–December 2006.
Variable Cases
𝑛
% Controls
𝑁
% Odds ratio 95% CI 𝑝 value
Age group (months)
≤36 35 15.2 248 36.9 1.00
37–60 95 41.3 272 40.4 2.48 1.62–3.78 <0.001
≥61 100 43.5 152 22.6 4.66 3.02–7.20 <0.001
Total 230 100.0 672 100.0
Sex
Female 109 47.4 353 52.5 1.00
Male 121 52.6 319 47.5 1.22 0.90–1.67 0.18
Total 230 100.0 672 100.0
Orphaned
No 133 59.1 543 83.1 1.00
Yes 92 40.9 110 16.9 3.42 2.44–4.78 <0.001
Total 225 100.0 653 100.0
Sibling died of AIDS
No 163 91.6 409 97.8 1.00
Yes 16 8.4 9 2.2 4.18 1.79–9.75 0.001
Total 178 100.0 418 100.0
Admission point
Outpatient clinic 74 32.2 450 67.0 1.00
Hospital 156 67.8 222 33.0 4.27 3.07–5.96 <0.001
Total 230 100.0 672 100.0
Antiretroviral treatment
No 54 33.3 76 39.0 1.00
Yes 108 66.7 119 61.0 1.28 0.83–1.97 0.27
Total 162 100.0 195 100.0
Mode of HIV transmission
Vertical 215 95.5 619 94.4 1.00
Others 10 4.5 37 5.6 0.78 0.38–1.59 0.49
Total 225 100.0 656 100.0
Immunodeficiency
Absent 7 3.0 392 58.6 1.00
Present 222 97.0 277 41.4 44.88 6.73–20.82 <0.001
Total 229 100.0 669 100.0
Clinical category of HIV (CDC)∗
Categories N and A 55 24.0 457 68.1 1.00
Categories B and C 174 76.0 214 31.9 6.76 4.79–9.53 <0.001
Total 229 100.0 671 100.0
∗Reference [20].
was 22%, the difference was not statistically significant (OR
= 0.78, 95: 0.48 to 1.26). Other studies conducted with HIV-
infected adults vaccinated with BCG in childhood have not
indicated any protective effect against TB [26, 27].
As in the case of adults, there are very few studies on the
protective effect of BCG in children. In Zambia, a hospital-
based case-control study (116 cases and 154 controls) did not
identify a protective effect of BCG against TB inHIV-infected
children: OR = 1.0; 95% CI: 0.2–4.6 [25]. However, the wide
CI suggests that the power of the study was not sufficient to
detect a protective effect.
In the global general population, mostly assumed to be
HIV-negative, BCG efficacy against pulmonary disease varies
[28–32], ranging from 0 [27] to around 80% [30, 31]. Several
explanations have been put forward concerning such vari-
ability, including the improper handling and administration
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Table 2: Odds ratios and effectiveness of the association between BCG vaccination and TB according to different diagnostic categories.
Hospital Pedia´trico David Bernardino (HPDB, Angola): January 2005–December 2006.
Variable
Tuberculosis
(all diagnostic categories) Control OR(95% CI) 𝑝 value
(1-OR) (%)
(95% CI)
𝑁 % 𝑁 %
BCG vaccination
No 86 37.4 239 35.6 1.00
Yes 144 62.6 433 64.4 0.92(0.68–1.26) 0.62
8
(−26–32)
Total 230 25.5 672 74.5
Variable
Tuberculosis
(confirmed diagnosis) Control OR(95% CI) 𝑝 value
(1-OR) (%)
(95% CI)
𝑁 % 𝑁 %
BCG vaccination
No 20 35.7 239 35.6 1.00
Yes 36 64.3 433 64.4 0.99(0.54–1.82) 0.90
1
(−82%–46%)
Total 56 7.7 672 92.3
Variable
Tuberculosis
(probable diagnosis) Control OR(95% CI) 𝑝 value
(1-OR) (%)
(95% CI)
𝑁 % 𝑁 %
BCG vaccination
No 66 37.9 239 35.6 1.00
Yes 108 62.1 433 64.4 0.90(0.63–1.29) 0.62
10
(−29–37)
Total 174 20.6 672 79.4
BCG: Bacille Calmette-Gue´rin; TB: tuberculosis; OR: odds ratio; CI: confidence interval; (1-OR) (%): BCG effectiveness.
Table 3: Odds ratios of the association between BCG vaccination
and TB adjusted for biological, family structure, healthcare, and
socioeconomic variables and clinical conditions.Hospital Pedia´trico
David Bernardino (HPDB, Angola): January 2005–December 2006.
Variables ORadjusted 95% CI 𝑝 value
BCG (adjusted for biological
variables)∗ 0.88 0.64 to 1.21 0.42
BCG (adjusted for family
structure variables)∗∗ 0.85 0.57 to 1.26 0.41
BCG (adjusted for healthcare
variables)∗∗∗ 0.79 0.40 to 1.56 0.50
BCG (adjusted for
socioeconomic variables)∗∗∗∗ 0.91 0.66 to 1.27 0.59
BCG (adjusted for clinical
condition variables)∗∗∗∗∗ 1.14 0.78 to 1.65 0.49
BCG: Bacille Calmette-Gue´rin; TB: tuberculosis; OR: odds ratio; CI: con-
fidence interval; ∗age; ∗∗age, orphaned, and sibling died of AIDS; ∗∗∗age,
admission point, adherence to antiretroviral treatment, distance to health
center, and regularity of AIDS consultations; ∗∗∗∗age, employment status,
number of people living in household, and housing conditions; ∗∗∗∗∗age,
previous history of pneumonia, clinical category of HIV infection (CDC),
and degree of immunodeficiency.
of the vaccine, exposure to nontuberculous mycobacteria
(NTM) in the periequatorial region, low immunogenicity of
the vaccine, concomitant malnutrition, and other infectious
diseases as well as a genetically determined low immune
response to the vaccine [33, 34]. The most widely accepted
explanation for the lack of protective effect against TB
observed in regions up to 30∘ latitude of Ecuador has been
a greater exposure to NTM [34–37]. These factors may also
be responsible for the lack of protection encountered in our
study; it is not clear how much the immunosuppression was
related to the lack of protection.
BCG scar reading has been used as an indicator of vaccine
status and became standard practice for assessing the pro-
tective effect of BCG in retrospective studies [38]. However,
scars may be absent due to administrating lower doses of
vaccine in childhood, the difficulty of injecting the entire
amount of vaccine and the relatively weak local immune
response in young children, or the probability that they may
even disappear with time [39]. Furthermore, scar formation
depends on the age of vaccination [40, 41], gender, [42] and
the fact that other scars may mimic the BCG scar [43].
In the present study, the absence of scarring on those who
had been vaccinated may have influenced the effectiveness,
since the vaccinated children who did not develop a scar (if,
for example, the vaccine no longer contained live BCG due to
inadequate storage) may have been considered unvaccinated,
thus generating a nondifferential misclassification, which
couldminimize the protective effect of the vaccine. A relevant
subsidy to this discussionwould be to discover the proportion
of vaccinated children in Angola who develop and maintain
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Table 4: Crude and adjusted effectiveness based on the presence of BCG scar for all children; crude effectiveness based on the vaccination card
and BCG scar for those children with a vaccination card. Hospital Pedia´trico David Bernardino (HPDB, Angola): January 2005–December
2006.
OR
(95% CI)
(1-OR) (%)
(95% CI)
Crude Adjusted∗ Crude Adjusted∗
All children based on BCG scar (𝑛 = 902) 0.92(0.68–1.26)
0.70
(0.28–1.75)
8
(−26–32)
30
(−75–72)
Children with vaccination card (𝑛 = 541)
Based on the vaccination card 0.71(0.44–1.14) —
29
(−14–56) —
Based on the BCG scar 0.84(0.53–1.32) —
16
(−32–47) —
∗Adjusted for sibling died of AIDS, regularity of AIDS consultations, adherence to antiretroviral treatment, degree of immunodeficiency, and clinical category
of HIV infection (CDC); variables that remained statistically significant in the intrablock multivariable analysis.
BCG: Bacille Calmette-Gue´rin; CI: confidence interval; OR: odds ratio; (1-OR) (%): effectiveness.
Table 5: Odds ratios and effectiveness of the association between BCG vaccination and TB (pulmonary and extrapulmonary). Hospital
Pedia´trico David Bernardino (Angola): January 2005–December 2006.
Variable Pulmonary tuberculosis Control OR(95% CI) 𝑝 value
(1-OR) (%)
(95% CI)
𝑁 % 𝑁 %
BCG vaccine
Yes 124 62.0 433 64.4 0.90(0.64–1.26) 0.58
10
(−26%–36%)
No 76 38.0 239 35.6 1.00
Total 200 22.9 672 77.1
Variable Extrapulmonary tuberculosis Control OR(95% CI) 𝑝 value
(1-OR) (%)
(95% CI)
𝑁 % 𝑁 %
BCG vaccination
Yes 20 66.7 433 64.4 1.10(0.48–2.57) 0.96
−10
(−157–52)
No 10 33.3 239 35.6 1.00
Total 30 4.3 672 95.7
BCG: Bacille Calmette-Gue´rin; TB: tuberculosis; OR: odds ratio; CI: confidence interval; (1-OR) (%): effectiveness.
scars. This proportion is around 60% in Sweden, 14 years
after vaccination [44], and 98.9% in India, four years after
vaccination [45]. Furthermore, development of protection
after BCG vaccination cannot be assumed by the formation
of a scar; there are no correlates of BCG protection.
To minimize misclassification bias, scar reading was
performed by suitably trained personnel blinded to the out-
come.Three infants, who presented with doubtful scars, were
excluded. The sensitivity and specificity of BCG scar reading
[46] were acceptable, suggesting no important classification
bias. When only the vaccination card was considered as the
gold standard, sensitivity was similar to that obtained in
Brazil [47], India [45], and Malawi [48].
Another group of reasons that could explain the lack
of protection is related to the different mechanisms of the
disease [27]. It has been hypothesized that BCG has a high
protective effect against newly acquired forms, the predom-
inant form in our study considering the age of the children,
and a low protective effect against endogenous reactivation
[49]. On the other hand, it has been suggested that protection
may only develop after three years of BCG vaccination [50];
a delay in development of protection would reduce the mea-
sured protection in a fraction of the children in our study as
the time elapsed since vaccination would not be long enough.
This study, through its characteristics, is unable to contribute
to this debate.
A further set of reasons relates to the high prevalence of
NTM via two proposed mechanisms, blocking and masking.
BCG appears to be sensitive to the influence of preexisting
immune responses to antigens shared by some strains of
NTM [51]. Previous sensitization to NTM could block the
development of protection. Alternatively, the higher preva-
lence of NTM would work as a “natural” vaccine against
TB (but not leprosy), masking the measurement of a BCG
protection that is still high, leading to variable efficacy against
tuberculosis [52].
One point against prior exposure to NTM as a cause of
BCG failure in this study is that, in Angola, BCG is given
at birth or at “the first contact with the health center,” and,
therefore, children would more likely be vaccinated before
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contact with NTM. However, interference from the MNT
protective effect cannot be excluded: the age of vaccination
was not recorded, but the percentage of births attended
by health personnel may suggest “late contact with the
health center,” hence allowing a previous contact with NTM.
Another point is that the prevalence of NTM as well as the
protective effect of BCG in HIV-negative children in Angola
is unknown.
Finally, low efficacy may simply be a consequence of HIV
infection and consequent immunodeficiency. In Zambia,
efficacy was 59% in noninfected children, while it was 0% in
infected children, although the studywas small and the power
was limited. In Argentina, a study on delayed complications
of BCG vaccination in HIV-infected children reported a
similar frequency of TB in both vaccinated and unvaccinated
children [53]. Most cases and controls in our study were
immunodeficient.
Lack of protection could potentially result from deficien-
cies in administrating the vaccine in addition to the above-
mentioned factors. To clarify this point, it would be necessary
to evaluate the quality of BCG vaccination, including the
administration technique and the cold chain maintenance
and management. This evaluation was beyond the scope of
our study.
The difference in the unadjusted effectiveness between
“all children” and the groups with vaccination scars may be
related to a reduction of the sample size and selection bias
introduced by this fact. Effectiveness was lower in those for
whom evaluation was based on the vaccination scar com-
pared to those for whom it was based only on the vaccination
card, since it was more probable that those who had been
vaccinated were in possession of a vaccination card.
The subgroup analysis (pulmonary and extrapulmonary)
was just exploratory as the sample size was not estimated
to make these comparisons. Effectiveness against the pul-
monary form was close to that obtained when considering
all forms of TB, reflecting the greater number of cases of
pulmonary forms.The lack of a protective effect against extra-
pulmonary TB is contrary to themajority of studies reporting
an effectiveness between 75% and 86% [6, 54]. Studies with
the most consistently high protection have focused on severe
extrapulmonary forms, meningeal and disseminated, which
constituted around 60% of the extrapulmonary forms of
the present study, possibly because of the exclusion of cases
below 18 months. As this study was not designed to evaluate
subgroups, the small number of cases limits the interpretation
of this result.
Due to certain limitations of this study, results need to be
interpreted with caution.
Refusal to participate, primary and secondary, though
occurring only amongst controls, had little or no influence
over the results because of low magnitude.
Owing to the difficulty of diagnosing pediatric TB, proba-
ble diagnosis was included as a category under study. Because
it is based on symptoms and signs and X-ray findings, it may
overlap with the findings of the HIV/AIDS, even in children
without TB [55, 56], leading to an underestimation of the
protective effect. However, the analysis, considering the two
diagnostic categories (confirmed and probable), establishes
the absence of a protective effect in immune deficient HIV-
infected children, suggesting that classification bias, should
there have been any, was minimal. Moreover the similarity
between probable and confirmed cases of TB and their differ-
ence from controls in relation to clinical criteria, TST, history
of contact with someone with TB, and HIV/AIDS related
variables suggests that the degree ofmisclassification bias was
not large.
The use of TST in the diagnosis of TB might lead to
overrecruitment of vaccinated cases which might have led
to an underestimation of efficacy. However, there was no
association between BCG vaccination and the induration size
of the TST either in cases or in controls. It is also possible
that the controls included a number of childrenwith unrecog-
nized TB; however, if vaccine is not protective, they are likely
to be not differentially distributed among controls with and
without BCG scars, which, therefore, would not change the
results.
The fact that this is a hospital-based study limits the gen-
eralization of results. However, HPDB is a Ministry of Health
national reference in providing free treatment and care for
children with HIV/AIDS. Some coinfected children may not
have come to the hospital; it will not bias the results if, as we
believe, it occurred similarly for vaccinated and unvaccinated
cases. Controls were selected from the same hospital as the
cases. As this is a reference hospital, cases and controls attend-
ing this service may have more severe forms of HIV/AIDS
but it is likely that controls were subject to the same
selection factors that influenced the cases to come to this
particular hospital, and thus they would be comparable to the
source population of the cases.
Since there is a lack of information regarding the precise
moment when the BCG vaccine was given (although they
were most likely not vaccinated at birth), we cannot exclude
the fact that a cohort effect may have occurred.
5. Conclusions
In our study sample, we did not detect any protective effect of
BCG vaccination against TB disease. BCG remains the only
tool available for the prevention of severe forms of TB inHIV-
uninfected children. Based on the evidence that children
who were HIV-infected when vaccinated with BCG at birth
were at increased risk of developing disseminated BCG
disease, WHO, in 2007, recommended that HIV-infected
children should not be vaccinated with BCG [17]. Following
WHO recommendation (based on fears of adverse events
and not on estimates of efficacy), no further studies will be
conducted to explore potential explanations for this lack of
protection. Although accepting that the findings of this study
are difficult to interpret and should be considered cautiously,
they are likely to be the last estimate of efficacy of BCG
in a predominantly immunodeficient, HIV-infected children
population in a sufficiently powered study. These data may
also be useful as a historical comparison when novel TB
vaccine candidates undergo clinical trials in HIV-infected
infants.
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